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The objective of the study was to determine lipid lowering efficacy of Pennisetum 
(P) glaucum (Pearl millet, locally known as bajra), bran in hyperlipidemia albino 
rats. Simvastatin, (Tablet survive®), was used as cholesterol lowering synthetic 
drug. The period of 0-15 days was considered as a lead-in period to induce 
hyperlipidemia with atherogenic diet in albino rats. P. glaucum bran at dose rate of 
2, 4 and 6 g/kg BW showed lipid lowering efficacy in hyperlipidemic rats at post-
treatment days 30, 45 and 60. At the level of 6 g/kg, P. glaucum bran was able to 
produce a significant (P<0.05) increase in HDL- cholesterol (47%) and fall in other 
lipid profile parameters i.e. total lipids (41%), triglycerides(48%), total cholesterol 
(39%) and LDL- cholesterol (55%). P. glaucum 6 g/kg also reduced total 
cholesterol in liver tissue and increased fecal bile acid secretion. The results of 
present study suggest that 6 g/kg P. glaucum bran and 0.6 mg/kg Simvastatin were 
equally effective in treating hyperlipidemia in albino rats. Moreover, the potency of 
P. glaucum for stimulating fecal bile acid secretion in albino rats may safely be 
conceived, at least, as a part of mechanisms for its antihyperlipidemic efficacy. 
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INTRODUCTION 
 
Increasing interests in atherosclerosis prevention and 
identification of hyperlipidemia as risk factor for ischemic 
heart disease have stimulated the study that started a new 
era in the treatment of atherosclerosis. In the last two 
decades both retrospective and prospective studies have 
shown strong correlation between levels of circulating 
lipids and mortality rates from coronary atherosclerotic 
heart disease (Anwar et al., 1999). Synthetic drugs used as 
antihyperlipidemic agent shows serious side effects (Javed 
et al., 1994; Javed et al., 2002). Therefore, attempts were 
focused on the Ayurvedic system of medicine to find out 
the drugs having hypolipidemic activity without side 
effects (Miura et al., 2003; Wei et al., 2003). 
  Dietary fibers have been reported to increase 
excretion of fecal bile acids resulting a fall in serum 
cholesterol (Timothy et al., 2003). In this respect, 
cellulose, metamucil and pectin have been found to 
enhance fecal elimination of cholesterol as bile acids 
leading to fall in serum cholesterol (Daggy et al., 1994). 
Moreover, dietary fibers may also increase the bulk of 
contents of intestine and so sequestering and diluting bile 
acids. Further, shorter transit of contents of intestine may 
cause decreased absorption of bile acids in distal portion 
of ileum (Mukherjee, 2010).   
Pennisetum glaucum, commonly known as pearl 
millet (Bajra), has been found to be appetizer and tonic. 
Its fruits have been reported as a useful therapy for open 
facial pimples (Chopra et al., 1986). P. glaucum, bran, has 
been considered a good source of dietary fiber (Nandini 
and Salimath, 2001). In view of these facts, the present 
project was designed for the pharmacological evaluation 
of P. glaucum bran for its antihyperlipidemic efficacy in 
albino rats. 
 
MATERIALS AND METHODS 
 
One hundred and eighty healthy adult male albino 
rats were purchased from the National Institute of Health, 
Islamabad, Pakistan. The animals were kept under the 
similar management conditions in animal room of 
Department of Clinical Medicine and Surgery, University 
of Agriculture, Faisalabad, Pakistan. The rats were housed 
in iron cages at ambient temperature with a 12/12 h period 
of light/dark. After seven days of acclimatization, the rats 
were randomly divided into six equal groups. The average 
body weight of all groups of albino rats ranged from 200 
to 300 g. The experiments were conducted with the prior 
approval by the Directorates of Research and Advanced 
Studies. The rats were sacrificed according to the rules 
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laid down by the Society of Ethics of Animals, University 
of Agriculture, Faisalabad, Pakistan.  
The rats were provided with normal routine rat feed 
(rat chow) for the first week of their arrival. The feed was 
made available twice a day, usually in morning and 
evening. However, drinking water was available 
throughout 24 hours. Expect one group, kept on normal 
routine rat feed, the rest of the groups were provided with 
atherogenic diet for 0-15 days. The period of 0-15 days 
was considered as a lead-in period to induce hyper-
lipidemia in albino rats. The atherogenic diet comprised of 
Cholesterol 0.5%, Coconut oil 20% and Cellulose 15%, 
mixed in normal routine rat feed (Aslam, 2005). 
Simvastatin, 20 mg (Tablet survive®), Werrick 
Pharmace- uticals, Islamabad, Pakistan) were used as 
cholesterol lowering synthetic drug. 
  The seeds of P. glaucum were procured from the 
Department of Botany, Faculty of Science, University of 
Agriculture, Faisalabad, Pakistan. The seeds were finely 
powdered with an electric grinder to get the flour of this 
medicinal plant. This flour was ultimately sieved to get 
the bran of P. glaucum. The bran was used for feeding to 
albino rats as an antihyperlipidemic indigenous medicinal 
plant drug. The drugs were thoroughly mixed with 
atherogenic diet and then fed to albino rats.  
Before the onset of present investigations, 
pharmacological screening of P. glaucum bran for its 
antihyperlipidemic activity and dosage was carried out in 
albino rats. Feeding schedule of normal routine rat feed, 
atherogenic feed, P.  glaucum  bran and Simvastatin in 
albino rats during the experimental period of 0 to 60 days 
has also been presented in Table 1. 
Blood samples were collected on 0, 15, 30, 45 and 60 
post treatment days. On each sampling day, 6 albino rats 
were slaughtered from each group and blood of individual 
albino rat was collected. The samples were allowed to clot 
for 20 minutes at refrigeration temperature and then 
centrifuged at 1968  x g for 5 minutes. Serum thus 
separated was stored at freezing temperature till analysis.  
At the completion of experiment, i.e. at post treatment 
day 60, the feces of rats of groups I, II, III and VI were 
collected separately. Afterwards, the rats of these groups 
were scarified and the liver of individual animals was 
removed free from fat and connective tissue. The fecal and 
liver samples were stored at -20°C until analysis.  
Cholic acid excreted in the feces was analyzed 
following method of Reinhold and Wilson (1934). Total 
cholesterol was extracted from the liver by a method 
described by Choi (1991). Lipid profile parameters 
including total lipids, triglycerides, total cholesterol, high 
density lipoprotein cholesterol (HDL-Cholesterol) and 
low density lipoprotein cholesterol (LDL-Cholesterol) 
were determined in the serum and total cholesterol in the 
extracts of liver of rats with reagent kits (Randox 
Laboratories Ltd, UK).  
The significance of the differences between the lead 
in period day 15 pre-treated and 30, 45 and 45 days post-
treated values was tested using Student’s T-test. To assess 
the antihyperlipidemic effect of P. glaucum bran on the 
cholesterol and cholic acid contents in the tissues of liver 
and feces, respectively, comparison between the treatment 
groups, treated control   group and/or untreated control 
group  was  performed  by analysis of variance (ANOVA)  
followed by Duncan’s Multiple Range Test (DMR). In all 
tests the criterion of statistical significance was (P<0.05). 
 
RESULTS AND DISCUSSION 
 
Hyperlipidemia was produced in normal healthy rats 
by feeding atherogenic diet from 0-15 days. Almost 2 
times increase was produced in lipid profile parameters 
i.e. total lipids, triglycerides, total cholesterol and LDL-
Cholesterol at day 15 than their respective values at day 0 
while HDL-Cholesterol has been found to show 
decreasing trend 1-1.5 times as compared to day 0 (Fig. 
1). However, 2.5-7 folds increase in lipid profile 
indicators have been reported in rabbit fed with 
atherogenic diet and cholesterol (400 mg/kg) for 90 days 
(Javed et al., 2009). Furthermore, 3.5-9 times increase in 
these parameters has been reported in albino rabbits fed 
with atherogenic diet and cholesterol (400 mg/kg) for 120 
days (Purohit and Daradka, 2001).  
 
0.00
2.00
4.00
6.00
8.00
10.00
12.00
0 days 15 days
C
o
n
c
e
n
t
r
a
t
i
o
n
(
m
m
o
l
/
l
)
Total liplids Triglycerides
Total Cholesterol HDL Cholesterol
LDL Cholesterol
 
Fig. 1: Mean (mg/dl) values of serum lipid profile in albino rats fed with 
atherogenic diet. 
 
After oral administration of P. glaucum bran at the doses 
of 2, 4 and 6 g/kg and Simvastatin at 0.6 mg/kg to 
hyperlipidemic albino rats, reductions in lead-in period 
day 15 pretreatment values of lipid profile parameters on 
post treatment days 30, 45 and 60 along with their 
respective percentage reductions have been presented in 
Tables 2-6.  
P. glaucum bran at the rate of 6 gm/kg resulted in a 
significant lowering (P<0.05) of total cholesterol of liver 
in comparison to routine feed fed rabbits (Table 7). 
Moreover, it is also evident from the Table 7 that the total 
cholesterol lowering effect of 6 g/kg of P. glaucum bran 
and Simvastatin is non-significantly different. 
As shown in Table 7, the level of cholic acid (mg/g) 
in the group of rabbits fed with 6 g/kg P. glaucum bran 
has been found significantly higher (P<0.05) than in those 
groups only on routine feed and simvastatin. Cholic acid 
is one of the constituents of bile prepared by cholesterol in 
the liver and necessary for emulsification of dietary fats 
making them suitable for on ward absorption from the 
intestine. Basically fiber forms a gel in the intestine that 
results in the binding of bile acids and secretion in feces. 
When an insufficient amount of cholesterol and bile acids 
reach the liver, the liver converts cholesterol to bile acids, 
thereby reducing cholesterol level in the serum (Patrick, 
2002; Hossain et al., 2011). Serum cholesterol loweringPak Vet J, 2012, 32(2): 201-205. 
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Table 1: Feeding schedule of normal routine rat feed, atherogenic feed, P. glaucum bran and Simvastatin in albino rats during the experimental period 
of 0 to 60 days. 
Treatment Plan  Group Group  Detail 
0-15 Days  16-60 Days 
I  Untreated control on normal routine feed  Routine rat feed  
II   Untreated control on AF  AF (Routine rat feed + cholesterol 0.5%, coconut oil 20%, Cellulose 15%)      
III   Treated control on synthetic cholesterol lowering drug; 
Tablet survive® (simvastatin) 
AF   AF+Tablets survive® (Simvastatin, 20 mg, 0.6 mg/kg) as cellulose 
replacement. 
IV   P. glaucum bran   AF   AF+bran 2 g/kg BW as cellulose replacement. 
V   P. glaucum bran   AF   AF+bran 4 g/kg BW as cellulose replacement. 
VI   P. glaucum bran   AF   AF+bran 6 g/kg BW as cellulose replacement. 
AF= Atherogenic feed  BW= Body weight 
 
Table 2: Values (Mean± SE) of total lipids (mg/dl) and their percentage reductions in the serum of hyperlipidemic rats (n=6) after treatment with P. 
glaucum bran and Simvastatin 
Post treatment days  Percentage reduction on post treatment days  Groups  Lead – in – Period Day 
15  30 45  60 30  45 60 
I  225.99±2.9    224.49±2.45    219.82±2.39     216.2±2.26  -  -  - 
II   391.29±3.1  439.05±3.1  512.44±2.6  579.43±2.5  -  -  - 
III   373.78±3.9    297.69±2.8*    216.49±2.5*   201.81±2.2*  20.39±3.10   42.08±3.46     46.0±3.96 
IV   405.45±2.7  384.41±2.8  360.69±2.6  355.81±2.1   5.18±3.2   11.03±3.41   12.24±4.12 
V   375.68±3.3  338.80±2.9  306.77±2.6  271.72±1.9   9.81±.67  18.34±2.5   27.67±3.51 
VI   366.26±2.4  310.02±2.6    257.61±2.8*    216.71±1.7*   15.36±3.27    29.66±3.76 
@40.83±3.93 
n=Number of animals in each group; *=significantly less (P≤0.05) than the pretreatment value at 15 days; @=Non-significantly (different from 
respective value obtained with Simvastatin. 
 
Table 3: Values (Mean± SE) of triglycerides (mg/dl) and their percentage reductions in the serum of hyperlipidemic rats (n=6) after treatment with P. 
glaucum bran and Simvastatin. 
Groups  Lead – in – Period Day 15  Post treatment days  Percentage reduction on post treatment days 
   30  45  60  30  45  60 
I   62.38±2.88    61.52±2.5    63.09±2.40   60.72±2.29  -  -  - 
II 127.66±1.81  142.40±1.9    163.52±1.6  194.0±1.1  -  -  - 
III  126.84±1.45  95.97±2.08*      61.6±1.84*    52.52±1.52*     24.33±2.1  51.45±2.28   58.59±2.73 
IV  132.39±2.69  121.47±2.48   111.27±2.41  101.12±2.06    9.24±1.47   15.95±1.71   23.61±2.47 
V  124.51±1.73  111.12±2.3  101.37±2.04  91.72±1.3  10.75±1.95   18.58±2.07   26.33±2.13 
VI  123.42±1.20  103.61±1.5   80.92±1.35*    62.98±1.02*  16.05±2.68  34.43±2.8 
@47.97±3.17 
n=Number of animals in each group; *=significantly less (P≤0.05) than the pretreatment value at 15 days; @=Non-significantly  different from 
respective value obtained with Simvastatin. 
 
Table 4:  Values (Mean± SE) of total cholesterol (mg/dl) and their percentage reductions in the serum of hyperlipidemic rats (n=6) after treatment 
with P. glaucum bran and Simvastatin 
Groups  Lead – in – Period Day 15  Post treatment days  Percentage reduction on post treatment days 
   30  45  60  30  45  60 
I    88.04±3.10   87.63±2.76   88.20±2.51   86.47±2.36  -  -  - 
II             144.44±1.3  162.62±2.87  190.81±2.60  212.05±2.40  -  -  - 
III  141.40±2.79    109.04±2 .47*     83.09±1.48*   76.13±1.37* 22.17±2.08  41.23±2.45 48.28±3.01 
IV  149.89±2.63  143.69±2.16  135.81±2.06  129.29±1.80      4.1±1.47    9.26±1.76  13.74±2.22 
V  135.05±1.97    124.86±1.9   112.87±1.7  98.89±1.6     9.55±1.67  18.23±2.02  28.36±3.25 
VI 133.75±2.58  113.52±2.10  96.53±1.8*    81.49±1.24*  15.12±3.15  27.82±3.68 
   @39.07±4.10 
n=Number of animals in each group; *=significantly less (P≤0.05) than the pretreatment value at 15 days; @=Non-significantly  different from 
respective value obtained with Simvastatin. 
 
Table 5: Values (Mean± SE) of HDL- cholesterol (mg/dl) and their percentage increases in the serum of hyperlipidemic rats (n=6) after treatment 
with P. glaucum bran and Simvastatin 
Groups  Lead – in – Period Day 15  Post treatment days  Percentage increase on post treatment days 
   30  45  60  30  45  60 
I 31.95±2.98  31.58±2.69  31.79±2.45  31.37±2.31  -  - - 
II 25.74±1.93  22.90±1.71  21.58±1.30  19.09±1.10  -  -  - 
III            23.265±1.79   30.68±1.89*      32.2±2.24*   34.79±2.91* 32.87±3.38 39.45±2.91  50.67±2.80 
IV 23.99±1.60  24.99±1.69  26.58±1.99  28.30±2.20  4.16±3.30  10.79±2.92  13.79±2.25 
V 26.91±1.61  28.40±1.91  29.77±2.56  30.29±2.80  5.5±2.02  10.62±1.80  15.18±1.60 
VI  22.2±2.4   26.88±1.98*    30.18±2.81*   32.78±3.14*  21.08±1.75  35.94±1.56 
@47.29±1.07 
n=Number of animals in each group; * =significantly higher (P≤0.05) than the pretreatment value at 15 days; @=Non-significantly different from 
respective value obtained with Simvastatin. 
 
Table 6:  Values (Mean± SE) of LDL- cholesterol (mg/dl) and their percentage reductions in the serum of hyperlipidemic rats (n=6) after treatment 
with P. glaucum bran and Simvastatin 
Groups  Lead – in – Period Day 15  Post treatment days  Percentage reduction on post treatment days 
   30  45  60  30  45  60 
I  43.61±3.16   43.75±2.65   41.47±2.53    40.56±2.46  -  -  - 
II 93.10±2.57  111.24±2.40    136.52±2.50  154.28±3.30  -  -  - 
III  89.27±3.52    59.27±1.67*   39.59±1.51*   37.52±1.38*  33.60±2.14  55.65±2.25   57.97±3.30 
IV 99.26±2.68 94.41±3.22    87.01±2.86  80.42±2.65      4.8±1.75  12.34±2.19   18.98±3.01 
V  86.19±1.21  74.24±2.32   62.83±2.02    50.27±1.8  13.86±2.19  27.10±2.80   41.67±3.78 
VI  86.87±2.05    66.01±1.86*   49.97±1.24*     39.24±1.05* 24.01±2.09 42.47±2.98 
@54.82±3.12 
n=Number of animals in each group; *=significantly less (P≤0.05) than the pretreatment value at 15 days; @=Non-significantly different from 
respective value obtained with Simvastatin. Pak Vet J, 2012, 32(2): 201-205. 
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Table 7: Total cholesterol (mg/g) in the liver and cholic acid (mg/g) in 
the feces of hyperlipidemic albino rats at post treatment day 60 after 
treatment with P. glaucum bran and Simvastatin  
Group  Total cholesterol (mg/g)  Cholic acid (mg/g) 
I  18.27±0.421B 80.2±3.6A 
II  33.21±0.480C 89.7±4.5B 
III  13.08±0.459A 78.1±3.2A 
VI  15.71±0.497A 98.6±5.1C 
Values (Mean±SE) followed by same letters indicate statistically non-
significant difference (P>0.05). 
 
effect of soyabean lecithin in rats (Polichetti et al., 1996) 
and cellulose, Metamucil and pectin in man (Mukherjee, 
2010) have been reported through promoting fecal 
elimination of cholesterol as bile acids. 
In the light of above results P. glaucum seed bran was 
able to reduce significantly (P<0.05) the level of total 
lipids, triglycerides, total cholesterol and LDL-cholesterol 
in serum of hyperlipidemic albino rats at the dose rate of 6 
g/kg feed, while serum HDL-cholesterol levels were 
increased. On post treatment day 60, the percentage 
reduction values of lipid profile and Simvastatin were 
found to be statistically similar (P<0.05). It can also be 
seen that P. glaucum barn at the dose of 6g/kg, amongst 
the lipid profile parameters reduced effectively LDL-
cholesterol, triglycerides, total lipids and total cholesterol 
as 55, 48, 41 and 39%, respectively. Moreover, it is 
evident that P. glaucum bran at the dose of 6g/kg 
increased the level of HDL-cholesterol 47%. However, 
40% reduction in serum total cholesterol was observed in 
hyperlipidemic rabbits fed with Cholestin, comprised of 
Meniscus purpurea rice and red yeast rice, while other 
lipid profile parameters remained statistically insignificant 
(Wei et al., 2003). On the other hand, Commiphora mukul 
as an adjunct to dietary therapy did not increase serum 
HDL-cholesterol in patients with hypercholesteremia 
(Singh  et al., 1994). However, gemfibrozil and niacin 
have been found associated with significant increase in 
HDL-cholesterol by 24% and the ratio of total cholesterol 
to HDL-cholesterol decrease by 30% (Spencer et al., 
1996). Moreover, triglycerides were reduced by 22% in 
70-80% patients treated with gugulipid (Nityanand et al., 
1989).  
A high fat diet is known to cause hyperlipidemia and 
there is a close relationship between atherosclerosis and 
an increase or decrease of serum lipids. In particular, 
LDL-cholesterol (bad cholesterol) may be risk factor and 
HDL-cholesterol (good cholesterol) may be a preventive 
factor. For the investigation of hypolipidemic activity, P. 
glaucum bran at dose rate 6g/kg and synthetic drug, 
Simvastatin, exhibited a significant lowering action on the 
serum levels of lipid profile parameters in albino rats. P. 
glaucum bran at dose rate 6 g/kg and Simvastatin induced 
respective percentage reductions in lipid profile 
parameters as 41 and 46% total lipids, 48 and 59% 
triglycerides, 39 and 48% total cholesterol and 55 and 58 
% LDL-cholesterol. However P. glaucum bran at dose 
rate 6 g/kg and Simvastatin induced percentage increase 
in HDL-cholesterol as 47 and 51%, respectively. Direct 
relationship has been reported between coronary 
atherosclerosis and high blood levels of cholesterol, 
triglycerides and LDL-cholesterol (Anonymous, 1984). 
However, there is an inverse relationship between blood 
HDL-cholesterol level and coronary heart disease 
(Jahromi  et al., 1993). After P. glaucum bran feeding, 
significant lowering of cholesterol (39%), triglycerides 
(47%) and LDL-cholesterol (55%) and increase in HDL-
cholesterol (47%) may be taken as an indicative of risk 
reduction action. It is clear that P. glaucum bran at dose 
rate of 6 g/kg and Simvastatin 0.6mg/kg appear to have 
equal potency on the basis of increasing the level of HDL-
cholesterol and decreasing the LDL-cholesterol. An 
increase in HDL-cholesterol and a reduction in LDL-
cholesterol would be clinically lucrative as apo-B-
containing lipoproteins are taken to be responsible for 
atherosclerosis (Choi et al., 1991). Thus, the clinical 
benefits of P. glaucum bran can be correlated with a fall 
in triglycerides, LDL-cholesterol and an increase in HDL-
cholesterol. A clinically advantageous effect of P. 
glaucum bran at dose rate 6g/kg may also be related with 
the reduction of atherogenic index (total cholesterol/HDL-
cholesterol) from 6.02 on lead-in day 15 to 2.49 on after 
treatment day 60. However, during this period Simvastatin 
reduced this ratio from 6.08 to 2.19.  
The results of present study suggest that P. glaucum 
bran at dose rate 6 g/kg and Simvastatin 0.6mg/kg body 
weight were equally effective in the treatment of hyperli- 
pidemic albino rats. Moreover, the potency of P. glaucum 
for stimulating fecal bile acid secretion in albino rats may 
safely be assumed, at least, as a part of mechanisms for its 
antihyperlipidemic efficacy. Further comprehensive 
chemical and pharmacological investigations are required 
to furnish the exact mechanism of these effects and also to 
isolate the active principle ingredients. 
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